Conference call at 8:00am EDT on Monday, June 16, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 9, 2014--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and orphan diseases, today announced it was hosting a conference call to
review the initial results from the HGB-205 Study to be presented on
Saturday June 14, 2014 at 04:15 pm CET (10.15 am EDT) at the 19th
Annual Congress of the European Hematology Association (EHA) in Milan,
Conference Call and Webcast
bluebird bio will host a conference call at 8:00 am EDT on Monday, June
16, 2014 to discuss the initial results from its HGB-205 Study.
Investors may listen to the webcast of the conference call live on the
"Calendar of Events" section of bluebird bio’s website, www.bluebirdbio.com.
Alternatively, investors may listen to the call: dialing (844) 825-4408
from locations in the U.S. and (315) 625-3227 from outside the U.S. The
webcast replay will be available for at least 48 hours following the
Other Upcoming Conferences
Management will also be presenting at the Jefferies Gene Therapy Summit
on June 16, 2014 at the W Hotel, Boston, Massachusetts; the Wells Fargo
Healthcare Conference on Wednesday June 18, 2014 at the Intercontinental
Hotel, Boston, Massachusetts; the Piper Jaffray GenomeRx Symposium on
June 23, 2014 at the Yale Club, New York, New York and the JMP
Healthcare Conference on June 25, 2014 at the Westin NY Grand Central,
To access a simultaneous webcast of the Wells Fargo and JMP
presentations via the internet, log on to the "Calendar of Events"
section on the Investor and Media page of the bluebird bio website at http://investor.bluebirdbio.com.
Please connect to the website at least ten minutes prior to the start of
the presentation to ensure adequate time for a reliable connection and
any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the
presentation in the "Calendar of Events" section of the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a recently-initiated
phase 2/3 study, the Starbeam Study, for the treatment of childhood
cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological
disorder affecting young boys. The next most advanced product candidate,
LentiGlobin, BB305 is currently in two phase 1/2 studies, one in the US
(the Northstar Study) and one in France (HGB-205), for the treatment of
beta-thalassemia major. The phase 1/2 HGB-205 study also allows
enrollment of patient(s) with sickle cell disease, and bluebird bio is
planning a separate U.S. sickle cell disease trial (HGB-206).
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in collaboration with Celgene
bluebird bio has operations in Cambridge, Massachusetts and Paris,
France. For more information, please visit www.bluebirdbio.com
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated milestones
related to the Company’s product candidates and clinical studies. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in the Company’s clinical
studies, the risk that the results of previously conducted studies
involving similar product candidates will not be repeated or observed in
ongoing or future studies involving current product candidates, the risk
that our collaboration with Celgene will not continue or will not be
successful, and the risk that any one or more of our product candidates
will not be successfully developed and commercialized. For a discussion
of other risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk Factors”
in our most recent annual report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
Availability of other information about bluebird bio
Investors and others should note that we communicate with our
investors and the public using our company website (www.bluebirdbio.com),
our investor relations website (http://www.bluebirdbio.com/investor-splash.html),
including but not limited to investor presentations and FAQs, Securities
and Exchange Commission filings, press releases, public conference calls
and webcasts. You can also connect with us on Twitter @bluebirdbio, LinkedIn
or our Youtube
channel. The information that we post on these channels and websites
could be deemed to be material information. As a result, we encourage
investors, the media, and others interested in bluebird bio to review
the information that we post on these channels, including our investor
relations website, on a regular basis. This list of channels may be
updated from time to time on our investor relations website and may
include other social media channels than the ones described above. The
contents of our website or these channels, or any other website that may
be accessed from our website or these channels, shall not be deemed
incorporated by reference in any filing under the Securities Act of 1933.
Source: bluebird bio, Inc.
bluebird bio, Inc.
Richard E. T.
Smith, Ph.D., 339-499-9382
Dan Budwick, 973-271-6085